Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
Tai Hato, Lipika Goyal, Tim F. Greten, Dan G. Duda, Andrew X. Zhu – 9 June 2014 – Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion.